Calidi Biotherapeutics (CLDI) Stock Analysis: AI Score & Alternative Data
CLDI alt-data: web traffic climbing, business outlook lagging
Is Calidi Biotherapeutics a buy right now? The alternative data says hold. This CLDI stock analysis is built on the 25+ alternative data signals AltIndex tracks on Calidi Biotherapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 45/100: a Hold. The stock trades at $1.39 with a $3M market cap.
The bullish side of the 90-day ledger: web traffic up 44.2% to 4K monthly visits, headcount (according to LinkedIn) up 10.3% to 32 employees, and sentiment up 33.3% to 100/100. The drag: just 44% of employees report a positive business outlook. That tension is what keeps the score mid-range.
CLDI’s broader alt-data profile also covers X followers (232). Every signal links to its own page with full history, the CLDI technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on CLDI is just below.
Calidi Biotherapeutics AI Stock Analysis
Calidi Biotherapeutics is a biotechnology company focused on advancing immunotherapies utilizing oncolytic viruses and stem cell-based treatments. The company specializes in developing innovative cancer treatments and has garnered attention for its pioneering approach in leveraging the body's immune system to combat cancer cells.
Analysis generated September 4, 2026.
Recent Calidi Biotherapeutics Stock Alerts
|
Calidi Biotherapeutics | September 2 Price is up by 6% in the last 24h. |
|
Calidi Biotherapeutics | August 19 Price is up by 10.2% in the last 24h. |
|
Calidi Biotherapeutics | August 18 Price is down by -6.6% in the last 24h. |
|
Calidi Biotherapeutics | August 17 Price is down by -6.3% in the last 24h. |
Calidi Biotherapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 4K | 44.2% | |
| Job Posts | 0 | 100.0% | |
| LinkedIn Employees | 32 | 10.3% | |
| Employee Recommend | 44 | 0% | |
| Business Outlook | 44 | 0% | |
| Sentiment | 100 | 33.3% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | 93.8% | |
| Stocktwits Mentions | 9 | 91.7% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 2K | 0% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 232 | 7.9% |
About Calidi Biotherapeutics (CLDI)
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors.
| Price | $1.39 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $3M |
| Year Range | $1 – $27 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Calidi Biotherapeutics News
View more →
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711July 8 - GlobeNewswire |
|
Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human StudyJune 16 - GlobeNewswire |
|
Calidi Biotherapeutics Provides Required NYSE American DisclosureMay 22 - GlobeNewswire |
|
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational HighlightsMarch 27 - GlobeNewswire |
|
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to ManufacturingMarch 12 - GlobeNewswire |
See Calidi Biotherapeutics’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for CLDI, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREECalidi Biotherapeutics Earnings & Financial Performance
View all earnings →Calidi Biotherapeutics Insider Trading Activity
View all →| Camaisa Allan filed to sell 76,952 shares at $0.0. Dec 12 '25 |
| Jackson Andrew C. filed to sell 2,500 shares at $0.0. Aug 21 '25 |
| Poma Eric E filed to sell 25,000 shares at $0.0. Aug 21 '25 |
| Schoeneck James A filed to sell 75,000 shares at $0.0. Aug 21 '25 |
| Leftwich Scott filed to sell 125,000 shares at $0.0. Aug 21 '25 |
Calidi Biotherapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Calidi Biotherapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
ScisparcSPRC |
$5.29 3.1% | $3M | 42 |
 |
Beyond AirXAIR |
$3.53 1.7% | $4M | 46 |
 |
60 DegreesSXTP |
$0.92 1.2% | $3M | 49 |
 |
BioRestorative TherapiesBRTX |
$0.15 3.0% | $4M | 48 |
 |
BioXcel TherapeuticsBTAI |
$0.07 37.1% | $4M | 41 |
Explore Calidi Biotherapeutics Data
Frequently Asked Questions: Calidi Biotherapeutics (CLDI)
Calidi Biotherapeutics has an AltIndex AI Score of 45/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
45/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Calidi Biotherapeutics (CLDI) stock is $1.39 with a market cap of $3M.
As of today, Calidi Biotherapeutics’s PE (Price to Earnings) ratio is —.
View the latest Calidi Biotherapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Calidi Biotherapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The CLDI stock price chart above shows Calidi Biotherapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Calidi Biotherapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Calidi Biotherapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
